Virtual family therapy may tame schizophrenia symptoms — a trial investigates
NCT ID NCT07121166
First seen Jul 24, 2026 · Last updated Jul 24, 2026
Summary
This trial tests whether a six-week online group program, combining cognitive behavioural therapy with family support, can help people with schizophrenia and their caregivers. Researchers will measure changes in symptoms, expressed emotion, and caregiver mood. The study includes 200 dyads and uses both surveys and interviews to gauge effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- a six-week online group cognitive behavioural family intervention (tgCBFI) for people with schizophrenia and their family caregivers
- What this could lead to
- If effective, this online program could offer a scalable way to improve symptoms and reduce caregiver stress without in-person visits.
- What could go wrong
- This is a relatively small trial with a short follow-up, and the benefits may not last or apply to all families. The intervention requires internet access and Chinese literacy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 200 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2025
- Expected to finish
-
Jul 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 64 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
I. Individuals with schizophrenia-spectrum disorders Inclusion Criteria: * current diagnosis of schizophrenia-spectrum disorders, based on ICD-10 made by the treating clinicians, * aged 18-64, and * able to read and write Chinese Exclusion Criteria: * having co-morbidity of learning disability, organic/neurological conditions, or substance use disorder, and * living in a hostel II. Family caregivers Inclusion Criteria: * aged 18 or above, * able to read and write Chinese, * live with service users, and * nominated by the service users Exclusion Criteria: * having active psychiatric conditions
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Schizophrenia are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
6 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
ALOHA (Eastern)
RECRUITINGChai Wan, Hong Kong
-
ALOHA (Wong Tai Sin)
RECRUITINGTsz Wan Shan, Hong Kong
-
Kowloon Hospital
RECRUITINGKowloon City, Hong Kong
-
Kwai Chung Hospital
RECRUITINGKwai Chung, Hong Kong
-
Queen Mary Hospital
RECRUITINGPokfulam, Hong Kong
-
United Christian Hospital
RECRUITINGKwun Tong, Hong Kong
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Your voice may reveal if You're taking your psychiatric medication
- Scientists probe brain's reward system in mental illness
- New schizophrenia drug targets brain glutamate, not dopamine
- New drug candidate takes aim at schizophrenia symptoms
- New schizophrenia drug goes Head-to-Head with standard antipsychotics in Long-Term trial
- Five-Year safety check for experimental schizophrenia drug